id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-E-0381-0008,FDA,FDA-2021-E-0381,Notice of Final Determination,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T16:13:35Z,,0,0,090000648647caf6
FDA-2021-E-0381-0007,FDA,FDA-2021-E-0381,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-02-02T05:00:00Z,2024,2,2024-02-02T05:00:00Z,,2024-02-02T20:17:36Z,,0,0,09000064863da611
FDA-2021-E-0381-0006,FDA,FDA-2021-E-0381,Determination of Regulatory Review Period for Purposes of Patent Extension; TISSUEBLUE,Notice,Determinations,2022-11-09T05:00:00Z,2022,11,2022-11-09T05:00:00Z,2023-01-10T04:59:59Z,2022-11-09T13:42:05Z,2022-24434,0,0,090000648549d0f1
FDA-2021-E-0381-0005,FDA,FDA-2021-E-0381,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2022-09-08T04:00:00Z,2022,9,2022-09-08T04:00:00Z,,2022-09-08T15:58:18Z,,0,0,09000064852cdb10
FDA-2021-E-0381-0004,FDA,FDA-2021-E-0381,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-10-12T04:00:00Z,2021,10,2021-10-12T04:00:00Z,,2021-10-12T17:49:37Z,,0,0,0900006484dc278c
FDA-2021-E-0381-0003,FDA,FDA-2021-E-0381,Letter to U S Patent and Trademark Office,Other,Letter(s),2021-06-08T04:00:00Z,2021,6,2021-06-08T04:00:00Z,,2021-06-08T15:04:08Z,,0,0,0900006484b5d51b
FDA-2021-E-0381-0002,FDA,FDA-2021-E-0381,"Patent Extension Application from Oblon, McClelland, Maier & Neustadt, P.C. (on behalf of Kyushu University, National University Corporation)",Other,Application,2021-04-13T04:00:00Z,2021,4,2021-04-13T04:00:00Z,,2021-04-13T14:29:03Z,,0,0,0900006484aa4ebc
FDA-2021-E-0381-0001,FDA,FDA-2021-E-0381,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-04-13T04:00:00Z,2021,4,2021-04-13T04:00:00Z,,2021-04-13T14:28:48Z,,0,0,0900006484aa4eba